A new class of cancer treatments that harness the body’s immune system to fight tumors is being hailed as the biggest thing in oncology since CAR-T revealed the promise of cell therapy more than a decade ago.
There’s a growing pipeline of cancer therapy candidates that harness a patient’s immune system to fight tumors.
During a sunny morning on Florida’s Gulf Coast last month, an 11-year-old golden retriever named Hunter bounded through a pine grove.
A Yale researcher developed a vaccine that can slow or halt certain cancers in dogs. And it could be used to treat humans in the future.
This year, Rockefeller scientists plumbed the depths of wound repair and tackled how songbirds solve problems; they used microchips to grow mini-lungs and proposed an environmental trigger for multiple sclerosis. Efforts to combat COVID, Hepatitis B, and other infections bore fruit, and countless papers shed light on basic research, answering questions that have long baffled biologists. Here are some of the intriguing discoveries that came out of Rockefeller in 2023.
As the male reproductive system ages, it becomes more and more susceptible to mutations. New research from the laboratory of Li Zhao explored this phenomenon in fruit flies, by focusing on how mutations arise during the formation of sperm. The team found that, while mutations are common in the testes of both young and old flies, the repair mechanisms that remove those mutations and maintain genomic integrity during spermatogenesis become less efficient in older individuals, leading to the accumulation and persistence of more mutations in older flies.
Computing has already accelerated scientific discovery. Now scientists say a combination of advanced AI with next-generation cloud computing is turbocharging the pace of discovery to speeds unimaginable just a few years ago.
Microsoft and the Pacific Northwest National Laboratory (PNNL) in Richland, Washington, are collaborating to demonstrate how this acceleration can benefit chemistry and materials science – two scientific fields pivotal to finding energy solutions that the world needs.
Scientists at PNNL are testing a new battery material that was found in a matter of weeks, not years, as part of the collaboration with Microsoft to use to advanced AI and high-performance computing (HPC), a type of cloud-based computing that combines large numbers of computers to solve complex scientific and mathematical tasks.
Microsoft presents LLMs in the Imaginarium.
Tool Learning through Simulated Trial and Error https://huggingface.co/papers/2403.
Tools are essential for large language models (LLMs) to acquire up-to-date information and take consequential actions in external environments.
Join the discussion on this paper page.
Chatbot Arena.
An open platform for evaluating llms by human preference.
Large Language Models (LLMs) have unlocked new capabilities and applications; however, evaluating the alignment with human preferences still poses significant challenges.
Join the discussion on this paper page.
The Robots Are Coming https://www.farzadmesbahi.com/merchFREE One Year Supply of Vitamin d3+k2 and 5 AG1 Travel Packs ➡ https://drinkAG1.com/farzadGet fit! M…
Freya India is a writer and journalist focussed on female mental health and modern culture. Gen Z girls are not doing ok. No matter how badly you think men have it right now (and they do), girls are doing no better.
The Rebellionaire Road Rally has made its way down to Austin, TX. This time we’re joined by Farzad (@farzyness) to test out Tesla FSD v12 on the streets of the greater Austin area. This is part 2 of the journey with Farzad joining in the car adding helpful commentary.
#Tesla #rebellionaire.
Rebellionaires check out www.Rebellionaire.com.
Rebellionaire is a brand of Halter Ferguson Financial. www.hffinancial.com/disclaimer.
As of March 7th, 2024, clients and employees of our firm Halter Ferguson Financial own Tesla stock and/or options and thereby stand to materially benefit from a rise in the share price. Past performance is no assurance of future results. Halter Ferguson Financial, Inc. (“Halter Ferguson Financial”) is a registered investment adviser with its principal place of business in the State of Indiana. A complete list of all recommendations will be provided if requested for the preceding period of not less than one year. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. Opinions expressed are those of Halter Ferguson Financial, Inc. and are subject to change, not guaranteed and should not be considered recommendations to buy or sell any security.
Halter Ferguson Financial is registered as an investment advisor with the SEC and only transacts business in states where it is properly registered, or is excluded or exempted from registration requirements. Registration as an investment advisor does not constitute an endorsement of the firm by the Commission nor does it indicate that the advisor has attained a particular level of skill or ability.
Information presented is believed to be factual and up-to-date, but we do not guarantee its accuracy and it should not be regarded as a complete analysis of the subjects discussed. All expressions of opinion reflect the judgment of the author/presenter as of the date of publication and are subject to change and do not constitute personalized investment advice. A professional advisor should be consulted before implementing any of the strategies presented. No content should be construed as an offer to buy or sell, or a solicitation of any offer to buy or sell any securities mentioned herein.
Thrombolytic therapy administered longer after the onset of ischemic stroke than current recommendations did not demonstrate improved clinical outcomes as compared to placebo, according to a recent trial published in the New England Journal of Medicine.
Minjee Kim, MD, associate professor in the Ken and Ruth Davee Department of Neurology’s Division of Neurocritical Care, was a co-author of the study.
Ischemic stroke occurs when a blood vessel supplying blood to the brain is blocked or reduced, and accounts for nearly 90% of all strokes, according to statistics from the American Stroke Association.
